AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04841148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCQ
Description: 600 mg tablets twice daily D1-28 of each 28-day cycle
Study NCT04841148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: 10 mg/kg, IV, D1 and D15 of each 28-day cycle
Study NCT04841148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: 125 mg capsule daily, by mouth on D1-21 concurrently with Avelumab. Or 75 mg capsule daily, by mouth on D1-28 concurrently with HCQ.
Study NCT05738096 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TSEPs recording only
Description: TSEPS will also be recorded from healthy controls in a lab setting; all procedures for the healthy controls will be non-invasive.
Study NCT06405490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab
Description: Use the above medications on a regular basis
Study NCT06067204 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual ventilation
Description: The adult size bag-valve mask is connected to the endotracheal tube, supraglottic airway or tracheostomy tube. The interval, pressure and volume of the ventilation is controlled by the emergency medical technicians.
Study NCT04717739 — intervention group
Intervention type: DEVICE
Intervention: TTFields
Description: Tumor Treating Fields (TTFields) help slow down or stop glioblastoma cancer cells from dividing by disrupting dividing mechanism of cancer cells leading to apoptosis. TTFields are low-intensity, intermediate frequency, alternating electric fields delivered continuously through adhesive patches, called transducer arrays, to the area of the brain where the GBM tumor is located. These transducer arrays are applied to the scalp and are connected to the wearable and portable device. TTFields are approved for the treatment of newly diagnosed and recurrent GBM.
Study NCT05753228 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI/ 3D Arterial Spin Labelling (ASL) and 1H magnetic resonance spectroscopy (MRS)
Description: MRI/ 3D Arterial Spin Labelling (ASL) and 1H magnetic resonance spectroscopy (MRS) to assess metabolic and mitochondrial perturbations in post-COVID fatigue or cancer fatigue.
Study NCT05984784 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Placebo Intravenous Infusion
Study NCT05984784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMG-007
Description: Drug: IMG-007 Intravenous Infusion
Study NCT05753228 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chalder Fatigue Scale
Description: The Chalder Fatigue Scale is used for measuring the extent and severity of fatigue within both clinical and non-clinical, epidemiological populations.
Study NCT05753228 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Questionnaire (EQ-5D-5L)
Description: The Health Questionnaire (EQ-5D-5L) is a self-report survey that measures quality of life across 5 domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is scored on a 5-level severity ranking that ranges from no problems through extreme problems.
Study NCT04837092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FR104
Description: FR104 treatment administration at day 0, day 14 then every 28 days until month 12
Study NCT04910542 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Epi-Net Intervention
Description: The Epidemiological Intelligence Network Intervention (Epi-Net) is a group of field epidemiology tools for test, trace and isolate using a community-based approach. The overall goal of Epi-Net is to increase uptake of COVID-19 testing and prevention practices among socially vulnerable communities in Puerto Rico. The intervention intends to impact COVID-19 risk perception, decrease COVID-19 testing barriers, increase testing uptake and increase health promotion strategies.
Study NCT06199401 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vascular Grafts Eversion and Built-in Technique(XJ-Procedure)
Description: A 1.5-2cm wide bovine pericardial patch and graft ring will be placed inside and outside the aortic root and against the aortic wall, respectively, and continuously sutured near the commissure using 5-0 polypropylene. Then an eversion about 15mm of vascular graft will be intermittently sutured to full layers of aortic vascular with 2-0 pad polyester suture. Finally, the eversion and aortic wall will be continuously sutured together in one more turn.
Study NCT04815746 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)-based skills
Description: The CBT skills target reducing anxiety, (e.g., relaxation), changing negative appraisals (e.g., cognitive restructuring), coping skills training (e.g., enhancing adaptive skills), behavioral activation, interpersonal skills (e.g., communication skills) and building or enhancing social networks. The intervention will be administered online, and each module will last about 1-hour.
Study NCT04815746 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Education
Description: Patients randomized to standard clinical care will receive standard education based on various resources (e.g., National Cancer Institute) relevant to pancreatic cancer.
Study NCT06005974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REC-4881
Description: REC-4881 4mg capsules
Study NCT06475118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamometry measurement, myokine dosing, sarcopenia calculation
Description: Blood sampling during standard pre-therapeutic care (at the same time with a standard blood testing) and dynamometry measurement. Retrieval of scanographic imaging and calculation of the L3 SMI index
Study NCT06129942 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright light box
Description: The light box uses a spectrally transparent prism diffuser, which can block ultraviolet rays, but will not affect the quality of the filtered light and will not turn yellow. The distance between the light box and the patient should not exceed 65cm.PD patients are selected for light intervention of different intensities. The experimental group is treated with 10,000 Lux intensity. The treatment time is 1 hour each day from 08:00-11:00 in the morning and 17:00-19:00 in the afternoon lasting for a month. The patient is asked to move under the light source, but should not fall asleep.
Study NCT06129942 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Dim Light box
Description: The light box uses a spectrally transparent prism diffuser, which can block ultraviolet rays, but will not affect the quality of the filtered light and will not turn yellow. The distance between the light box and the patient should not exceed 65cm.PD patients are selected for light intervention of different intensities. The control group is treated with 300 Lux intensity. The treatment time is 1 hour each day from 08:00-11:00 in the morning and 17:00-19:00 in the afternoon lasting for a month. The patient is asked to move under the light source, but should not fall asleep.
Study NCT06099782 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab co-formulated with hyaluronidase
Description: Fixed dose coformulated product of hyaluronidase/pembrolizumab adminstered via SC injection.
Study NCT06099782 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab co-formulated with hyaluronidase
Description: Fixed dose coformulated product of hyaluronidase/pembrolizumab adminstered via SC injection.
Study NCT06099782 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered via IV infusion
Study NCT06099782 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Administered via IV infusion
Study NCT05442216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tagraxofusp (Cycles 1-2)
Description: 12 mcg/kg intravenously Days 1-5
Study NCT05442216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75 mg/m2 intravenously Days 1-7 (Cycle 3-12)
Study NCT05442216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tagraxofusp (Cycles 3-12)
Description: 12 mcg/kg intravenously Days 1-3
Study NCT06567769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC1130A
Description: ICV injection
Study NCT05753228 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hamilton Depression Rating Scale
Description: The Hamilton Depression Rating Scale is a multiple-item questionnaire used to provide an indication of depression, and as a guide to evaluate recovery.
Study NCT04550039 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Body-weight-supported treadmill
Description: Gait training performed on treadmill with overhead harness providing necessary body-weight-support with assistance from trained physical therapist
Study NCT04550039 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ekso Bionics EksoNR exoskeleton
Description: Gait training performed overground in EksoNR exoskeleton with assistance from trained physical therapist
Study NCT03106376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 16% O2 gas in breathed air
Description: Inspiratory gas mixtures: Hypoxic inspiratory gas will be obtained by adding nitrogen (N2) to normobaric, normoxic air with medical N2 tanks.~Delivery of gas mixture: The gas mixture will be delivered by standard tight facemask.
Study NCT03106376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 26% O2 gas in breathed air
Description: Inspiratory gas mixtures: Hyperoxic inspiratory gas will be obtained by adding oxygen (O2) to normobaric, normoxic air with medical O2 tanks.~Delivery of gas mixture: The gas mixture will be delivered by standard tight facemask.
Study NCT05717335 — intervention group
Intervention type: DRUG
Intervention: TachoSil
Description: Placement of TachoSil over the ventricular entry point in patients with periventricular lesions in order to avoid complications related to the ventricular entry.
Study NCT06566586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3702 tablets+Chemotherapy regimen
Description: TQB3702 tablets: Tyrosine kinase inhibitor；~Chemotherapy regimen：inhibiting tumor cell proliferation, suppressing DNA synthesis, inducing cell apoptosis, enhancing immune system function, and inhibiting angiogenesis；
Study NCT06454344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-i)
Description: CBT-I is a structured program with a robust empirical evidence supporting its efficacy for improving sleep quality and quantity. The cognitive component of CBT-I teaching individuals how to recognize and change the beliefs they hold about sleep that negatively impact sleep, such as negative thoughts and emotions. The behavioral component includes several strategies to help improve sleep, including: improved sleep hygiene, improving the sleep environment, relaxation training, stimulus control therapy (consistent wake/sleep times, using the bed only for sleep, etc), and sleep restriction. Sleep restriction consists of reducing the time spend in bed initially to increase sleep drive in subsequent nights. Once sleep has improved, the time in bed is gradually increased again.
Study NCT06481774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CONNECT platform
Description: CONNECT platform provides access to participant information across the 5 participant sites to facilitate a more holistic approach to addressing participant needs. It is the use of this cloud-based, HIPAA compliant platform that constitutes the uniqueness of this behavioral intervention.
Study NCT05669833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab (GUS) subcutaneous injection
Study NCT05669833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Golimumab
Description: Golimumab (GOL) subcutaneous injection
Study NCT04751383 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT04751383 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study NCT04751383 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT04751383 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT04768673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-393 formulation I
Description: single, oral administration of 2 tablets under fed condition
Study NCT04751383 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dinutuximab
Description: Given IV
Study NCT04751383 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04768673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-393 formulation II
Description: single, oral administration of 2 tablets under fed condition
Study NCT04768673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D501, D759, H053
Description: single, oral administration of 1 D501, 1 D759 and 2 H053 under fed condition
Study NCT06252298 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTC21C
Description: SCTC21C is injected to the participants subcutaneously and is tentatively scheduled to be administered weekly for the first two cycles, once every 2weeks for cycle3-6, and once every 4 weeks thereafter until the occurrence of progressive disease
Study NCT05584566 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OSSIX Breeze
Description: barrier membrane
Study NCT05584566 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jason membrane
Description: barrier membrane
Study NCT05430919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5713
Description: Administered subcutaneously (SC)
Study NCT05430919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5714
Description: Administered SC
Study NCT05430919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5715
Description: Administered SC
Study NCT05430919 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT05430919 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC
Study NCT04751383 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Given IV
Study NCT04751383 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo surgical resection
Study NCT06365047 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 8% Arginine toothpaste
Description: Investigative
Study NCT06365047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1000 ppm F toothpaste
Description: Control
Study NCT06214806 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Grocery Vouchers
Description: Participants will be given vouchers to buy groceries each month for five months.
Study NCT06214806 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Grocery Vouchers
Description: Participants will be given vouchers to buy groceries each month for five months.
Study NCT05732987 — intervention group
Intervention type: OTHER
Intervention: Analysis of samples
Description: DNA extraction from blood or saliva samples for the identification of gene variants by next generation sequencing;
Study NCT06310967 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IG3018
Description: Oral administration
Study NCT06310967 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo matching IG3018
Description: Oral administration
Study NCT05732987 — intervention group
Intervention type: OTHER
Intervention: Analysis of samples
Description: RNA extraction from blood and skin samples for Nanostring analyses, quantitative RT-PCR or RNA sequencing.
Study NCT05998291 — intervention group
Intervention type: OTHER
Intervention: Assessment of prognosis of refractory dermatitis herpetiformis. No intervention
Description: Assessment of prognosis of refractory dermatitis herpetiformis. No intervention
Study NCT05129189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC22 group
Description: The trial group received ASC22 1mg/kg hypodermic injection Q4W and Chidamide 10mg PO BIW.
Study NCT05732987 — intervention group
Intervention type: OTHER
Intervention: Analysis of samples
Description: Biobanked skin samples will be analyzed by immunostaining and imaging techniques to identify cell types in lesions and compare them to healthy skin.
Study NCT05732987 — intervention group
Intervention type: OTHER
Intervention: Analysis of samples
Description: Cells isolated from biobanked blood and skin samples will be cultured in vitro and proteins will be analyzed by ELISA (secreted proteins) and western blot (cell proteins).
Study NCT06150755 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: implant supported overdenture by ball
Description: overdenture supported by two implant with ball attachment
Study NCT06150755 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant supported overdenture by bar
Description: overdenture supported by two implant splinted by intraoral welding titanuim bar
Study NCT05695196 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nasal microbiota transplant (NMT)
Description: nasal microbiota transplant
Study NCT05695196 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sterile saline
Study NCT06145906 — intervention group
Intervention type: PROCEDURE
Intervention: Pulmonary vein isolation plus superior vena cava isolation
Description: Pulmonary vein isolation plus superior vena cava isolation
Study NCT06285357 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EGCG + folic acid + B12
Description: EGCG + folic acid + B12
Study NCT06145906 — intervention group
Intervention type: PROCEDURE
Intervention: PVI, superior vena cava isolation, and linear ablation of linear ablations of the mitral isthmus, roofline and posterior wall line of the left atrium, and cavotricuspid isthmus
Description: PVI, superior vena cava isolation, and linear ablation of linear ablations of the mitral isthmus, roofline and posterior wall line of the left atrium, and cavotricuspid isthmus
Study NCT06637215 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic colorectal day surgery
Description: laparoscopic colorectal day surgery in patients with colorectal tumor who are generally in good health and have sufficient organ functions
Study NCT06637215 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: traditional laparoscopic colorectal surgery
Description: traditional laparoscopic colorectal surgery in patients with colorectal tumor who are generally in good health and have sufficient organ functions
Study NCT05722938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimodulin
Description: IMP will be administered via IV infusion on 5 consecutive days
Study NCT05722938 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (human albumin 1%)
Description: IMP will be administered via IV infusion on 5 consecutive days
Study NCT06392971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deep-sea fish oil
Description: Starting from radiotherapy, the whole course of prophylactic oral deep-sea fish oil should be taken at the recommended dosage of 1g po bid according to the instructions (the administration method is to take it with the drug, remove the film on the drug surface, slowly swallow it in a supine position, and make the liquid fully contact with the esophageal mucosa). If no acute radioactive esophagus was assessed during the course of treatment, the patient was administered orally until the end of radiotherapy. If the patient developed radioactive esophagitis during the course of treatment, the relevant outcome measures were recorded and used as the endpoint event of the phase I study. The end point for patients without acute radiation esophagitis was at the completion of radiation therapy.
Study NCT06392971 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take a capsule made of food oil that looks like deep-sea fish oil at a dose of 1g po bid. Treatment is discontinued when patients develop acute radiation esophagitis.
Study NCT05627765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard treatment (ST) arm
Description: Participants will receive a brief smoking cessation intervention based on the asking about tobacco use, Advising smokers to quit, Assessing their willingness to quit,Assisting in quitting, and Arranging for follow-up and relevance, risks, rewards, roadblocks and repetition models at baseline. Booster interventions will be provided to ST arm at 1-week, 1-month, 3-month, and 6-month follow-up.
Study NCT05627765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Intervention (II) arm
Description: Participants will receive brief advice on alcohol use based on the FRAMES model, which is a well-established and effective brief intervention for drinking.
Study NCT05983692 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnesium based wire
Description: Mg wire will be used as a braiding suture to braid tendon graft, which is a standard preparation of graft and is not related to fixation of the tendon graft